# Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

> **NCT02678312** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 393 (actual)

## Conditions studied

- Pediatric Heart Failure

## Interventions

- **DRUG:** LCZ696
- **DRUG:** Enalapril
- **DRUG:** Placebo of LCZ696
- **DRUG:** Placebo of Enalapril
- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT02678312
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-03
- **Primary completion:** 2022-01-03
- **Final completion:** 2022-01-03
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678312, "Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02678312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*